0001179110-20-011989.txt : 20201216
0001179110-20-011989.hdr.sgml : 20201216
20201216160337
ACCESSION NUMBER: 0001179110-20-011989
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201214
FILED AS OF DATE: 20201216
DATE AS OF CHANGE: 20201216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boral Anthony L.
CENTRAL INDEX KEY: 0001638468
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 201392452
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2020-12-14
0
0001597264
Blueprint Medicines Corp
BPMC
0001638468
Boral Anthony L.
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2020-12-14
4
M
0
10000
15.01
A
38147
D
Common Stock
2020-12-14
4
S
0
7815
118.72
D
30332
D
Common Stock
2020-12-14
4
S
0
1970
117.92
D
28362
D
Common Stock
2020-12-14
4
S
0
215
116.75
D
28147
D
Stock Option (Right to Buy)
15.01
2020-12-14
4
M
0
10000
0
D
2026-02-03
Common Stock
10000
7483
D
Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.32 to $119.315 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.39 to $118.30 per share.
This option was granted on February 3, 2016. This option is fully vested as of the date hereof.
/s/ Christopher Frankenfield, Attorney-in-Fact
2020-12-16